View in EDS HTML Full Text PDF Full Text

Plasma WFDC2 (HE4) as a Predictive Biomarker for Clinical Outcomes in Cancer Patients Receiving Anti-PD-1 Therapy: A Pilot Study.

Saved in:
Bibliographic Details
Title: Plasma WFDC2 (HE4) as a Predictive Biomarker for Clinical Outcomes in Cancer Patients Receiving Anti-PD-1 Therapy: A Pilot Study.
Authors: Watanabe M; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo 157-8577, Japan.; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo 157-8577, Japan.; Department of Pharmacology, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.; Pharmacological Research Center, Showa Medical University, Tokyo 142-8555, Japan., Ieguchi K; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo 157-8577, Japan.; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo 157-8577, Japan., Shimizu T; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo 157-8577, Japan.; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo 157-8577, Japan., Ohkuma R; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.; Showa Medical University Comprehensive Cancer Information Center, Showa Medical University, Tokyo 142-8555, Japan., Suzuki R; Department of Pharmacology, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.; Pharmacological Research Center, Showa Medical University, Tokyo 142-8555, Japan.; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan., Mura E; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan., Iriguchi N; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan., Ishiguro T; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan., Hirasawa Y; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan., Ikeda G; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan., Shimokawa M; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan., Ariizumi H; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan., Yoshimura K; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo 157-8577, Japan.; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan., Horiike A; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan., Tsunoda T; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.; Showa Medical University Comprehensive Cancer Information Center, Showa Medical University, Tokyo 142-8555, Japan., Tsuji M; Pharmacological Research Center, Showa Medical University, Tokyo 142-8555, Japan., Kobayashi S; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo 157-8577, Japan., Oguchi T; Department of Pharmacology, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.; Pharmacological Research Center, Showa Medical University, Tokyo 142-8555, Japan., Kiuchi Y; Department of Pharmacology, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan., Wada S; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo 157-8577, Japan.; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo 157-8577, Japan.; Department of Pharmacology, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.
Source: Cancers [Cancers (Basel)] 2025 Jul 18; Vol. 17 (14). Date of Electronic Publication: 2025 Jul 18.
Publication Type: Journal Article
Journal Info: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40723266
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Plasma WFDC2 (HE4) as a Predictive Biomarker for Clinical Outcomes in Cancer Patients Receiving Anti-PD-1 Therapy: A Pilot Study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Watanabe+M%22">Watanabe M</searchLink>; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo 157-8577, Japan.; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo 157-8577, Japan.; Department of Pharmacology, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.; Pharmacological Research Center, Showa Medical University, Tokyo 142-8555, Japan.<br /><searchLink fieldCode="AU" term="%22Ieguchi+K%22">Ieguchi K</searchLink>; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo 157-8577, Japan.; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo 157-8577, Japan.<br /><searchLink fieldCode="AU" term="%22Shimizu+T%22">Shimizu T</searchLink>; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo 157-8577, Japan.; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo 157-8577, Japan.<br /><searchLink fieldCode="AU" term="%22Ohkuma+R%22">Ohkuma R</searchLink>; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.; Showa Medical University Comprehensive Cancer Information Center, Showa Medical University, Tokyo 142-8555, Japan.<br /><searchLink fieldCode="AU" term="%22Suzuki+R%22">Suzuki R</searchLink>; Department of Pharmacology, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.; Pharmacological Research Center, Showa Medical University, Tokyo 142-8555, Japan.; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.<br /><searchLink fieldCode="AU" term="%22Mura+E%22">Mura E</searchLink>; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.<br /><searchLink fieldCode="AU" term="%22Iriguchi+N%22">Iriguchi N</searchLink>; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.<br /><searchLink fieldCode="AU" term="%22Ishiguro+T%22">Ishiguro T</searchLink>; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.<br /><searchLink fieldCode="AU" term="%22Hirasawa+Y%22">Hirasawa Y</searchLink>; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.<br /><searchLink fieldCode="AU" term="%22Ikeda+G%22">Ikeda G</searchLink>; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.<br /><searchLink fieldCode="AU" term="%22Shimokawa+M%22">Shimokawa M</searchLink>; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.<br /><searchLink fieldCode="AU" term="%22Ariizumi+H%22">Ariizumi H</searchLink>; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.<br /><searchLink fieldCode="AU" term="%22Yoshimura+K%22">Yoshimura K</searchLink>; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo 157-8577, Japan.; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.<br /><searchLink fieldCode="AU" term="%22Horiike+A%22">Horiike A</searchLink>; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.<br /><searchLink fieldCode="AU" term="%22Tsunoda+T%22">Tsunoda T</searchLink>; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.; Showa Medical University Comprehensive Cancer Information Center, Showa Medical University, Tokyo 142-8555, Japan.<br /><searchLink fieldCode="AU" term="%22Tsuji+M%22">Tsuji M</searchLink>; Pharmacological Research Center, Showa Medical University, Tokyo 142-8555, Japan.<br /><searchLink fieldCode="AU" term="%22Kobayashi+S%22">Kobayashi S</searchLink>; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo 157-8577, Japan.<br /><searchLink fieldCode="AU" term="%22Oguchi+T%22">Oguchi T</searchLink>; Department of Pharmacology, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.; Pharmacological Research Center, Showa Medical University, Tokyo 142-8555, Japan.<br /><searchLink fieldCode="AU" term="%22Kiuchi+Y%22">Kiuchi Y</searchLink>; Department of Pharmacology, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.<br /><searchLink fieldCode="AU" term="%22Wada+S%22">Wada S</searchLink>; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo 157-8577, Japan.; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo 157-8577, Japan.; Department of Pharmacology, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101526829%22">Cancers</searchLink> [Cancers (Basel)] 2025 Jul 18; Vol. 17 (14). <i>Date of Electronic Publication: </i>2025 Jul 18.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22MDPI%22">MDPI </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101526829 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Print <i>ISSN: </i>2072-6694 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220726694%22">20726694 </searchLink><i>NLM ISO Abbreviation: </i>Cancers (Basel) <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40723266
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3390/cancers17142384
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Plasma WFDC2 (HE4) as a Predictive Biomarker for Clinical Outcomes in Cancer Patients Receiving Anti-PD-1 Therapy: A Pilot Study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Watanabe M
      – PersonEntity:
          Name:
            NameFull: Ieguchi K
      – PersonEntity:
          Name:
            NameFull: Shimizu T
      – PersonEntity:
          Name:
            NameFull: Ohkuma R
      – PersonEntity:
          Name:
            NameFull: Suzuki R
      – PersonEntity:
          Name:
            NameFull: Mura E
      – PersonEntity:
          Name:
            NameFull: Iriguchi N
      – PersonEntity:
          Name:
            NameFull: Ishiguro T
      – PersonEntity:
          Name:
            NameFull: Hirasawa Y
      – PersonEntity:
          Name:
            NameFull: Ikeda G
      – PersonEntity:
          Name:
            NameFull: Shimokawa M
      – PersonEntity:
          Name:
            NameFull: Ariizumi H
      – PersonEntity:
          Name:
            NameFull: Yoshimura K
      – PersonEntity:
          Name:
            NameFull: Horiike A
      – PersonEntity:
          Name:
            NameFull: Tsunoda T
      – PersonEntity:
          Name:
            NameFull: Tsuji M
      – PersonEntity:
          Name:
            NameFull: Kobayashi S
      – PersonEntity:
          Name:
            NameFull: Oguchi T
      – PersonEntity:
          Name:
            NameFull: Kiuchi Y
      – PersonEntity:
          Name:
            NameFull: Wada S
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 18
              M: 07
              Text: 2025 Jul 18
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 2072-6694
          Numbering:
            – Type: volume
              Value: 17
            – Type: issue
              Value: 14
          Titles:
            – TitleFull: Cancers
              Type: main
ResultId 1